{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreignidesqfrl5o6srtn7oun6q4lyaflaz47zust3sbgprv46w62dqm",
    "uri": "at://did:plc:7nuyhqvd4a6xquezhjhvregv/app.bsky.feed.post/3mkvi2z5dkqk2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreihcj6houkmlepnhvgkg246p5gofkbq2abe3nffi3pifv424cytqye"
    },
    "mimeType": "image/jpeg",
    "size": 427368
  },
  "path": "/2026/05/02/us/abortion-pill-mifepristone-5th-circuit-court-ruling.html",
  "publishedAt": "2026-05-02T19:11:33.000Z",
  "site": "https://www.nytimes.com",
  "tags": [
    "Abortion Drugs",
    "Telemedicine",
    "Mifeprex (RU-486)",
    "American College of Obstetricians and Gynecologists",
    "Suits and Litigation (Civil)",
    "Birth Control and Family Planning",
    "Louisiana",
    "Food and Drug Administration"
  ],
  "textContent": "The Fifth Circuit court’s ruling, which is being appealed, reinstates a requirement that patients visit a health care provider in person to obtain mifepristone, upending abortion access in the United States.",
  "title": "Abortion Providers Forced to Adapt After Court Ruling Blocks Pill Access by Mail"
}